Objective: To study effect of Pioglitazone on serum high density lipoprotein levels in patients with type 2 diabetes mellitus.
Study Design: Single blind randomized controlled trial
Place and Duration of Study: Department of medicine, Combined Military Hospital Multan from 1st Feb 2011 to 30th July 2012.
Material and Methods: A total of 276 already diagnosed patients of diabetes mellitus type 2 between age of 30-80 years, presenting to the outpatient department of Combined Military Hospital Multan were selected. Type 2 diabetic patients were allocated group A or B using random allocation. Base line blood sugar fasting (BSF), glycosylated hemoglobin (HbA1c), high density lipoprotein (HDL) levels were taken. Group A was treated with Pioglitazone along with other hypoglycemic agents while group B was treated with only hypoglycemic agents and multivitamin tablets were added as placebo.After 12 weeks of treatment, serum HDL levels were measured to analyze effect of pioglitazone on serum HDL levels.
Results: Pioglitazone group showed significant improvement in the serum HDL levels from baseline HDL 46.38 + 6.44mmol/L to 49.80+ 5.86 mmol/L after 12 weeks of therapy, (p = 0.001).
Conclusion: Pioglitazone when used in combination with other oral hypoglycemic agents has a beneficial effect on the serum HDL levels of the diabetics.
Diabetes Mellitus, High density lipoprotein, Pioglitazone.